Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Juvederm Users: Cosmetic Dermatologists (US)

Articles with lock require a subscription to GLG News | Request a free trial
March 6, 2008
The Outlook of AS1409 for Melanoma
Analysis of: Antisoma starts phase I clinical trial of AS1409 in renal cancer and melanoma | www.pipelinereview.com
Author: GLG Expert Contributor
Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) today announces the entry of AS1409 into clinical trials. A phase I trial has started in patients with renal cancer and melanoma. The trial has two parts. In the first, successive cohorts of patients will receive increasing doses of AS1409....
March 5, 2008
Phosphagenics’s Retinoic Acid will Enter a Crowded Field if Approved
Analysis of: Phosphagenics Initiates US Clinical Trials For Its Topical Retinoic Acid | www.pipelinereview.com
Author: GLG Expert Contributor
Phosphagenics’s topical retinoic acid, aided with their proprietary drug delivery platform, has shown significant reduction in irritation scores in their pre-clinical studies for the treatment of acne.
March 4, 2008
Humira will overtake Enbrel in the TNF alpha market
Analysis of: Abbott Receives FDA Approval for Humira (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis | pharmalive.com
Author: GLG Expert Contributor
This is Humira’s 6th indication, and 2nd within the last 2 months.  It was approved for moderate to severe chronic plaque psoriasis in Jan 2008. 
March 4, 2008
Did Amgen use improper tactics to raise sales of Enbrel?
Analysis of: Two former Amgen salespeople allege improper drug marketing | articles.latimes.com
Author: GLG Expert Contributor
Marc Engelman, a former drug representative for Enbrel, claimed that Amgen required salespeople to gain access to patient medical information in doctors' offices.  The alleged intent was to market the drug directly to patients, several of whom may not have needed the medication.
March 4, 2008
How will this discovery affect future psoriasis therapies?
Analysis of: Researchers call Th17 immune cells primary regulators of psoriasis | dermatologytimes.modernmedicine.com
Author: GLG Expert Contributor
Th17 cells were found to be three times greater in the skin in psoriasis patients compared that of healthy people.
March 4, 2008
Ustekinumab for moderate to severe chronic plaque psoriasis
Analysis of: Promising Phase 3 Data for Ustekinumab (Cnto 1275) in Long-Term Improvement of Chronic Plaque Psoriasis | www.jnj.com
Author: GLG Expert Contributor
Their findings (directly from the website)- Investigators reported findings from PHOENIX 1 that showed at week 12, after two doses, 67 percent of patients receiving 45 mg ustekinumab and 66 percent of patients receiving 90 mg ustekinumab achieved PASI 75 (compared with 3 percent of patients receiving...
March 4, 2008
How well does Enbrel work for pediatric psoriasis?
Analysis of: New Study Reports Enbrel (etanercept) Significantly Improved Moderate to Severe Plaque Psoriasis in Children and Adolescents | www.wyeth.com
Author: GLG Expert Contributor
Their findings (directly from the website)- During the 48-week study, the percentage of patients achieving 75 percent or greater disease improvement from baseline, as measured by the standard Psoriasis Area and Severity Index (PASI 75), was used to evaluate the efficacy of ENBREL in patients between...
March 4, 2008
HUMIRA versus Enbrel
Analysis of: Abbott's HUMIRA® (adalimumab) Receives FDA Approval for Moderate to Severe Chronic Plaque Psoriasis | www.abbott.com
Author: GLG Expert Contributor
HUMIRA has been in the dermatology arena ever since it was approved for psoriatic arthritis.  Dermatologists could prescribe HUMIRA for their psoriatic patients who also had a component of arthritis.  However, 60-90% of psoriatic patients have psoriatic arthritis.  ...
March 4, 2008
ABT-874 for Moderate to Severe Chronic Plaque Psoriasis
Analysis of: Safety and Efficacy of ABT-874, a Fully Human Interleukin 12/23 Monoclonal Antibody, in the Treatment of Moderate to Severe Chronic Plaque Psoriasis | archderm.ama-assn.org
Author: GLG Expert Contributor
ABT-874 was studied in a phase 2, 12-week, multicenter, randomized, double-blind, placebo-controlled trial for Moderate to Severe Chronic Plaque Psoriasis.  180 Patients were randomized to receive 1 of 6 treatments: one 200-mg dose at week 0; 100 mg every other week for 12 weeks; 200 mg weekly...
Sunil DhawanFebruary 12, 2008
FDA Botox warning unlikely to limit cosmetic use
Analysis of: FDA Issues Warning About Botox Deaths | www.pharmalot.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
The recent FDA warning on Botox is unlikely to limit the cosmetic use of the product because the dose is relatively low. The warning only applies to significantly  higher doses in patients with neuromuscular conditions like cerebral palsy. Serious adverse events like allergic reactions are very...

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next51 to 60 of 188

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T13:45:22.747